Seed Amplification Assays for Parkinson's Disease: A Review of α-Synuclein Assays in Body Fluids and Tissues - PubMed
a day ago
- #Parkinson's Disease
- #Diagnostic Accuracy
- #α-Synuclein Assays
- Seed amplification assays (SAAs) enable highly sensitive detection of pathological α-synuclein in Parkinson's disease.
- Cerebrospinal fluid-based RT-QuIC shows 93.3-94.6% sensitivity and 94% specificity for diagnosing sporadic Parkinson's and dementia with Lewy bodies.
- Alternative samples like skin and intestinal tissues offer up to 94.1% diagnostic accuracy, providing less invasive options.
- SAAs can distinguish between Parkinson's disease/Lewy body dementia and multiple system atrophy via strain typing.
- In prodromal screening, SAAs show over 80% positivity in idiopathic REM sleep behavior disorder, detecting disease years before clinical diagnosis.
- Limitations include small sample sizes, lack of multicenter validation, and standardization issues affecting consistency.
- Future work should focus on standardization, integration of digital biomarkers, and broader validation for clinical implementation.